Long-Term Outcomes Most users report lasting benefit after completing a full treatment protocol and appropriate rest period
Available in-studio and mobile
Dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, which means it mimics the action of these incretin hormones to enhance insulin secretion, suppress glucagon release, and slow gastric emptying
Advanced dosing strategies for experienced users Once you have gone through the standard titration and found a dose that works, there are several strategies that experienced users and prescribers employ to optimize outcomes further
Some patients notice changes sooner than others, while some goals may require more time and follow-up
Although research is still in the preclinical stage, TB4 (Fragment 1-4) represents a promising approach to enhance gut repair, promote epithelial recovery, and support overall intestinal barrier function in models of gastrointestinal injury